April 18, 2014
Sanofi K.K. Diabetes Business Unit Head Steve Sugino The market of sodium-glucose co-transporter 2 (SGLT-2) inhibitors, for the treatment of type 2 diabetes, is expected to become highly competitive this year in Japan. Following the launch of Astellas Pharma’s Suglat...read more